[go: up one dir, main page]

MA29946B1 - Nouvelles compositions ameliorees pour la therapie du cancer - Google Patents

Nouvelles compositions ameliorees pour la therapie du cancer

Info

Publication number
MA29946B1
MA29946B1 MA30925A MA30925A MA29946B1 MA 29946 B1 MA29946 B1 MA 29946B1 MA 30925 A MA30925 A MA 30925A MA 30925 A MA30925 A MA 30925A MA 29946 B1 MA29946 B1 MA 29946B1
Authority
MA
Morocco
Prior art keywords
methods
improved compositions
cancer therapy
new improved
composition
Prior art date
Application number
MA30925A
Other languages
English (en)
Inventor
Amarjit Singh
Sarabjit Singh
Ajay K Gupta
Mangesh M Kulkarni
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of MA29946B1 publication Critical patent/MA29946B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSITIONS NOUVELLES ET AMÉLIORÉES DE MÉDICAMENTS ANTICANCÉREUX, DE PRÉFÉRENCE DES TAXANES, TELS QUE LE PACLITAXEL ET LE DOCÉTAXEL, LEURS DÉRIVÉS OU LEURS ANALOGUES, DES PROCÉDÉS DE FABRICATION DE CES COMPOSITIONS ET DES PROCÉDÉS DE FRACTIONNEMENT DES PARTICULES PAR PLAGE DE TAILLE PARTICULIÈRE ET DES PROCÉDÉS DE TRAITEMENT DE PATIENTS CANCÉREUX AVEC CES COMPOSITIONS, QUI PRODUISENT DES EFFETS SECONDAIRES INDUITS PAR UNE CHIMIOTHÉRAPIE RÉDUITS EN PARTICULIER UNE ALOPÉCIE INDUITE PAR UNE CHIMIOTHÉRAPIE RÉDUITE. LA COMPOSITION EST TELLE QU'IL N'Y A SENSIBLEMENT PAS DE MÉDICAMENT LIBRE DANS LADITE COMPOSITION.
MA30925A 2005-10-21 2008-05-15 Nouvelles compositions ameliorees pour la therapie du cancer MA29946B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1327MU2005 2005-10-21
IN1081MU2006 2006-07-10

Publications (1)

Publication Number Publication Date
MA29946B1 true MA29946B1 (fr) 2008-11-03

Family

ID=38163340

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30925A MA29946B1 (fr) 2005-10-21 2008-05-15 Nouvelles compositions ameliorees pour la therapie du cancer

Country Status (13)

Country Link
US (1) US20100166872A1 (fr)
EP (1) EP1962906A4 (fr)
JP (1) JP2009512682A (fr)
AR (1) AR058130A1 (fr)
AU (1) AU2006324872B2 (fr)
BR (1) BRPI0617663A2 (fr)
CA (1) CA2626016A1 (fr)
CR (1) CR9989A (fr)
EA (1) EA015781B1 (fr)
IL (1) IL190882A0 (fr)
MA (1) MA29946B1 (fr)
RS (1) RS20080167A (fr)
WO (1) WO2007069272A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2231144B1 (fr) 2007-12-24 2014-07-02 Sun Pharma Advanced Research Company Limited Nanodispersion
US8865223B2 (en) 2008-02-11 2014-10-21 Technion Research And Development Foundation Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
EP2252269A1 (fr) * 2008-02-11 2010-11-24 Technion Research and Development Foundation, Ltd. Particules de caséine encapsulant des agents thérapeutiquement actifs et leurs utilisations
US8865222B2 (en) 2008-02-11 2014-10-21 Technion Research And Development Foundation Ltd. Beta-casein assemblies for enrichment of food and beverages and methods of preparation thereof
US8871276B2 (en) 2008-02-11 2014-10-28 Technion Research And Development Foundation Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
GB0818747D0 (en) 2008-10-13 2008-11-19 Univ Nottingham Biocompatible responsive materials
EP2266546A1 (fr) 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Procédé pour la préparation de systèmes colloïdaux pour la livraison de composés actifs
CA2765541A1 (fr) 2009-06-19 2010-12-23 Sun Pharma Advanced Research Company Ltd. Nanodispersion d'un medicament et son procede de preparation
WO2011017835A1 (fr) * 2009-08-11 2011-02-17 Nanjing University Procédé de préparation de nanoparticules protéiques ou peptidiques pour l'administration de médicaments in vivo par déploiement et repliement
CN102665689B (zh) * 2009-09-21 2015-04-22 Jw制药公司 奥沙利铂纳米颗粒及其制备方法
MX341082B (es) 2010-05-03 2016-08-08 Teikoku Pharma Usa Inc Formulaciones de pro-emulsion de taxano no acuosas y metodos para hacer y usar las mismas.
EP2575783B1 (fr) * 2010-06-01 2017-01-11 Geistlich Pharma AG Méthodes et compositions de traitement pharmaceutique par voie orale
WO2012058462A2 (fr) * 2010-10-29 2012-05-03 Isis Pharmaceuticals, Inc. Polythérapie destinée au traitement du cancer
US10285943B2 (en) 2010-12-02 2019-05-14 Greenmark Biomedical Inc. Aptamer bioconjugate drug delivery device
JP6038881B2 (ja) 2011-04-20 2016-12-07 ザ・ユニバーシティ・オブ・シドニー 治療の方法及びそのために有用な剤
US9364433B2 (en) 2011-04-28 2016-06-14 Borje S. Andersson Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
WO2013124867A1 (fr) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US10143700B2 (en) 2013-02-19 2018-12-04 Amrita Vishwa Vidyapeetham Nanoparticle formulations for delivering multiple therapeutic agents
EP2983674A4 (fr) 2013-04-08 2017-05-10 Dennis M. Brown Bénéfice thérapeutique de composés chimiques administrés de façon sous-optimale
LT3046584T (lt) 2013-09-16 2017-10-10 Astrazeneca Ab Terapinės polimerinės nanodalelės ir jų gamybos būdai ir panaudojimas
KR20150047336A (ko) 2013-10-24 2015-05-04 삼성전자주식회사 나노입자, 이를 제조하는 방법, 및 이의 용도
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN103739672B (zh) * 2013-12-31 2015-06-10 威特曼生物科技（南京）有限公司 一种聚乙二醇修饰的抑制vegfr2酪氨酸激酶多肽及其应用
RU2591819C2 (ru) * 2014-03-03 2016-07-20 Закрытое акционерное общество "СКАЙ ЛТД" Способ получения фолликулярного белкового препарата и препарат, полученный данным способом
HRP20251032T1 (hr) 2015-02-01 2025-10-24 Quetzal Therapeutics, Llc Liofilizirani pripravci s visokim površinskim područjem koji sadrže arsen za oralnu primjenu kod pacijenata
EP3265063A4 (fr) 2015-03-03 2018-11-07 Cureport, Inc. Formulations pharmaceutiques liposomales à double charge
WO2016141167A1 (fr) 2015-03-03 2016-09-09 Cureport, Inc. Formulations pharmaceutiques liposomales en combinaison
CN106137969B (zh) 2015-04-03 2020-05-15 四川科伦药物研究院有限公司 多西他赛白蛋白纳米粒药物组合物及其制备方法及应用
IL285928B2 (en) 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
WO2018200393A1 (fr) * 2017-04-24 2018-11-01 Zy Therapeutics Inc. Composition pharmaceutique pour l'administration in vivo, procédé de préparation d'un principe pharmacologiquement actif sensiblement insoluble dans l'eau
WO2019028457A2 (fr) * 2017-08-04 2019-02-07 University Of Houston System Formulation d'une nanosuspension de diéthylstilbestrol injectable
US11666515B2 (en) 2018-03-28 2023-06-06 Greenmark Biomedical Inc. Phosphate crosslinked starch nanoparticle and dental treatments
EP3829307A4 (fr) 2018-07-31 2022-08-03 Microbion Corporation Compositions de bismuth-thiol et méthodes d'utilisation
MX2021001276A (es) * 2018-07-31 2021-07-15 Microbion Corp Composiciones de bismuto-tiol y metodos para tratar heridas.
FR3087650B1 (fr) * 2018-10-31 2021-01-29 Bio Even Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer
CN114767879A (zh) * 2022-06-02 2022-07-22 平顶山学院 一种多西紫杉醇恶性肿瘤靶向微球及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
WO1994026254A1 (fr) * 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation de taxol dans des liposomes et des gels
PT1023050E (pt) * 1997-06-27 2013-12-04 Abraxis Bioscience Llc Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
AU784416B2 (en) * 1999-05-21 2006-03-30 Abraxis Bioscience, Llc Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
JP2003520210A (ja) * 2000-01-05 2003-07-02 イマレックス セラピューティクス， インコーポレイテッド 低い水溶性を有する薬物の送達のための薬学的処方物
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
EP1585504A4 (fr) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Preparations liposomales d'agents pharmaceutiques stabilisees par des proteines
KR20110079741A (ko) * 2002-12-09 2011-07-07 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법

Also Published As

Publication number Publication date
WO2007069272A2 (fr) 2007-06-21
WO2007069272A3 (fr) 2007-08-23
EP1962906A2 (fr) 2008-09-03
JP2009512682A (ja) 2009-03-26
AR058130A1 (es) 2008-01-23
RS20080167A (sr) 2009-07-15
EA200801132A1 (ru) 2009-02-27
EA015781B1 (ru) 2011-12-30
AU2006324872B2 (en) 2012-03-08
AU2006324872A1 (en) 2007-06-21
CR9989A (es) 2008-07-18
EP1962906A4 (fr) 2009-11-18
CA2626016A1 (fr) 2007-06-21
IL190882A0 (en) 2008-11-03
BRPI0617663A2 (pt) 2011-08-02
US20100166872A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
MA29946B1 (fr) Nouvelles compositions ameliorees pour la therapie du cancer
WO2009120697A4 (fr) Méthode et compositions pour le traitement du cancer
EP2481402A3 (fr) Nanoparticule comportant du rapamycine et albumine en tant qu'agent anti-cancer
MA31497B1 (fr) Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c
MA33299B1 (fr) Nouvelle formulation de naproxène
HUP0400203A2 (hu) Epotilon analógok és kemoterápiás szerek kombinációja proliferatív betegségek kezelésére alkalmas gyógyszerkészítmény előállítására
EP1819227A4 (fr) Formulation pharmaceutique de decitabine
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
FI952248A7 (fi) Kasvainvastaisia koostumuksia, jotka sisältävät taksaanijohdannaisia
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
EP1951729A4 (fr) Derives de pyrimidine a liaison oxygene
WO2007139930A3 (fr) Associations de médicaments comportant des urées de diaryle substituées pour le traitement du cancer
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA34308B1 (fr) Triazolopyridines substituées
WO2008105852A3 (fr) Nanoparticules mucoadhésives pour traitement anticancéreux
MA30325B1 (fr) Composes qui potentialisent le recepteur ampa et leurs utilisations en medecine
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
HUT75513A (en) Taxane class derivative based pharmaceutical compositions and their preparation
FR2952372B1 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
NO994408D0 (no) Dolastatin-15 derivater i kombinasjon med taxaner
FR3059236B1 (fr) Extraits de plantes du genre tagetes et leurs utilisations
PE20061090A1 (es) Preparaciones de taxanos sustituidos con esteres de ciclopropilo en c10
UA95088C2 (ru) Композиция, которая содержит наночастички связанные с биосовместимым полимером противоракового агента и снижает аллопецию при химиотерапии, способ ее получения
EA201391327A1 (ru) Терапевтическое лечение
TNSN08171A1 (en) Pharmaceutical composition comprising at least one anticancer drug and at least one polymer